AI Engines For more Details: Perplexity Kagi Labs You
Reduction of Triglycerides: Gemfibrozil is effective in lowering triglyceride levels in the blood. High triglyceride levels are associated with an increased risk of cardiovascular disease.
Increase in HDL Cholesterol: Gemfibrozil can also raise high-density lipoprotein (HDL) cholesterol levels, often referred to as "good" cholesterol. HDL helps remove low-density lipoprotein (LDL) cholesterol from the arteries, reducing the risk of atherosclerosis and cardiovascular disease.
Decrease in LDL Cholesterol: While gemfibrozil primarily targets triglycerides and HDL cholesterol, it may also modestly reduce low-density lipoprotein (LDL) cholesterol levels, commonly known as "bad" cholesterol.
Cardiovascular Risk Reduction: By lowering triglycerides and increasing HDL cholesterol levels, gemfibrozil can help reduce the risk of cardiovascular events such as heart attacks and strokes, particularly in individuals with hypertriglyceridemia.
Improvement in Lipid Profile: Gemfibrozil treatment often results in an overall improvement in lipid profile, characterized by lower triglyceride levels, higher HDL cholesterol levels, and sometimes modest reductions in LDL cholesterol.
Prevention of Pancreatitis: High triglyceride levels are a risk factor for pancreatitis (inflammation of the pancreas). By lowering triglyceride levels, gemfibrozil may help reduce the risk of pancreatitis in susceptible individuals.
Potential Side Effects: Common side effects of gemfibrozil include gastrointestinal symptoms such as abdominal pain, diarrhea, nausea, and indigestion. Some individuals may also experience muscle pain or weakness, which can be a sign of myopathy or rhabdomyolysis (muscle breakdown). These side effects are usually reversible upon discontinuation of the medication.
Interactions with Other Medications: Gemfibrozil can interact with certain medications, including statins (cholesterol-lowering drugs), leading to an increased risk of myopathy or rhabdomyolysis. It is important to consult a healthcare professional before starting gemfibrozil if taking other medications.
Liver Function Monitoring: Gemfibrozil may affect liver function, and periodic monitoring of liver enzymes may be necessary during treatment, particularly in individuals with pre-existing liver conditions.
Contraindications: Gemfibrozil is contraindicated in individuals with severe liver or kidney disease, gallbladder disease, or a history of hypersensitivity to the medication.
Long-Term Use: The long-term safety and efficacy of gemfibrozil have been established in numerous clinical trials. However, like any medication, it should be used with caution, and regular monitoring may be necessary, especially in individuals with multiple risk factors for cardiovascular disease.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
species | Bifidobacterium adolescentis | Reduces |
species | Bifidobacterium longum | Reduces |
species | Escherichia coli | Reduces |
species | Lacticaseibacillus paracasei | Reduces |
subspecies | Bifidobacterium longum subsp. infantis | Reduces |
subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.4 | -0.4 | |
ADHD | 3.8 | 0.1 | 37 |
Age-Related Macular Degeneration and Glaucoma | 0.4 | 0 | 0 |
Allergic Rhinitis (Hay Fever) | 0.4 | 2 | -4 |
Allergies | 3 | 1.3 | 1.31 |
Allergy to milk products | 0.4 | 0.5 | -0.25 |
Alopecia (Hair Loss) | 0.6 | 0.6 | |
Alzheimer's disease | 2.3 | 2.6 | -0.13 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.9 | 0.4 | 3.75 |
Ankylosing spondylitis | 1.6 | 0.6 | 1.67 |
Anorexia Nervosa | 0 | 1 | 0 |
Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
Asthma | 0.8 | 1 | -0.25 |
Atherosclerosis | 0.9 | 1.3 | -0.44 |
Atrial fibrillation | 1.6 | 0.7 | 1.29 |
Autism | 4.7 | 4.5 | 0.04 |
Barrett esophagus cancer | 0.6 | 0.2 | 2 |
benign prostatic hyperplasia | 0 | 0 | |
Bipolar Disorder | 0.3 | 0.6 | -1 |
Brain Trauma | 0.6 | 0.5 | 0.2 |
Carcinoma | 1.9 | 1.6 | 0.19 |
Celiac Disease | 1.1 | 2.7 | -1.45 |
Cerebral Palsy | 1.2 | 0.7 | 0.71 |
Chronic Fatigue Syndrome | 2.8 | 2.8 | 0 |
Chronic Kidney Disease | 0.7 | 0.5 | 0.4 |
Chronic Lyme | 0.5 | -0.5 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 0.4 | 1.75 |
Chronic Urticaria (Hives) | 0.7 | 0.6 | 0.17 |
Coagulation / Micro clot triggering bacteria | 0.3 | 0.7 | -1.33 |
Colorectal Cancer | 2.5 | 0.6 | 3.17 |
Constipation | 0.3 | 0.5 | -0.67 |
Coronary artery disease | 0.2 | 0.5 | -1.5 |
COVID-19 | 6.6 | 6.3 | 0.05 |
Crohn's Disease | 4.1 | 2.8 | 0.46 |
cystic fibrosis | 0.1 | 0.9 | -8 |
deep vein thrombosis | 0.1 | 0.4 | -3 |
Depression | 6.7 | 3.6 | 0.86 |
Dermatomyositis | 0.2 | 0.4 | -1 |
Eczema | 0.3 | 0.9 | -2 |
Endometriosis | 1.3 | 0.7 | 0.86 |
Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
Epilepsy | 2 | 1.5 | 0.33 |
Fibromyalgia | 0.8 | 1.1 | -0.38 |
Functional constipation / chronic idiopathic constipation | 2.5 | 2.1 | 0.19 |
gallstone disease (gsd) | 0.8 | 1 | -0.25 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.8 | 0.7 | 0.14 |
Generalized anxiety disorder | 0.6 | 1.5 | -1.5 |
giant cell arteritis | 0.1 | -0.1 | |
Glioblastoma | 0.2 | -0.2 | |
Graves' disease | 0.8 | 0.8 | 0 |
Halitosis | 0.8 | 0.2 | 3 |
Hashimoto's thyroiditis | 1.7 | 0.6 | 1.83 |
Hidradenitis Suppurativa | 0.5 | 0.3 | 0.67 |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 2.2 | 0.4 | 4.5 |
hypercholesterolemia (High Cholesterol) | 0.5 | 0.4 | 0.25 |
hyperglycemia | 0 | 1.5 | 0 |
Hyperlipidemia (High Blood Fats) | 0.8 | 0.2 | 3 |
hypersomnia | 0.3 | -0.3 | |
hypertension (High Blood Pressure | 1.2 | 3.8 | -2.17 |
Hypothyroidism | 0.8 | -0.8 | |
Hypoxia | 0.4 | 0.4 | |
IgA nephropathy (IgAN) | 1.6 | -1.6 | |
Inflammatory Bowel Disease | 1.5 | 3.3 | -1.2 |
Insomnia | 0.7 | 0.6 | 0.17 |
Intelligence | 0.5 | 0.5 | |
Intracranial aneurysms | 0.5 | 0.2 | 1.5 |
Irritable Bowel Syndrome | 2.3 | 2.5 | -0.09 |
Liver Cirrhosis | 2.8 | 1.7 | 0.65 |
Long COVID | 3.6 | 4.9 | -0.36 |
Low bone mineral density | 0.4 | -0.4 | |
Lung Cancer | 0.7 | 0.7 | 0 |
ME/CFS with IBS | 0.5 | 1.4 | -1.8 |
ME/CFS without IBS | 0.8 | 1 | -0.25 |
Menopause | 2.1 | 2.1 | |
Metabolic Syndrome | 4.1 | 5.8 | -0.41 |
Mood Disorders | 8 | 3.8 | 1.11 |
multiple chemical sensitivity [MCS] | 0.6 | 0.3 | 1 |
Multiple Sclerosis | 3.4 | 1.6 | 1.13 |
Multiple system atrophy (MSA) | 1.4 | 0.7 | 1 |
Neuropathy (all types) | 0.6 | 0 | 0 |
neuropsychiatric disorders (PANDAS, PANS) | 0.4 | 0.4 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.9 | 3.8 | -3.22 |
NonCeliac Gluten Sensitivity | 0.4 | -0.4 | |
Obesity | 4.7 | 2.4 | 0.96 |
obsessive-compulsive disorder | 3.3 | 2 | 0.65 |
Osteoarthritis | 0.6 | 0.6 | |
Osteoporosis | 0.8 | 0.8 | 0 |
pancreatic cancer | 0.6 | 0.6 | |
Parkinson's Disease | 1.5 | 1.6 | -0.07 |
Polycystic ovary syndrome | 0.7 | 1.3 | -0.86 |
Postural orthostatic tachycardia syndrome | 0.1 | 0.4 | -3 |
Premenstrual dysphoric disorder | 0.8 | 0 | 0 |
primary biliary cholangitis | 0.1 | 0.6 | -5 |
Psoriasis | 2.3 | 1 | 1.3 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.1 | 2.4 | 0.29 |
Rosacea | 0.6 | 0.4 | 0.5 |
Schizophrenia | 4.7 | 1 | 3.7 |
scoliosis | 0.2 | -0.2 | |
Sjögren syndrome | 1.7 | 2.2 | -0.29 |
Sleep Apnea | 1 | 0.9 | 0.11 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.8 | -0.33 |
Stress / posttraumatic stress disorder | 1.7 | 1.7 | 0 |
Systemic Lupus Erythematosus | 2 | 1.4 | 0.43 |
Tic Disorder | 0.4 | 0.7 | -0.75 |
Tourette syndrome | 0.2 | 0.2 | 0 |
Type 1 Diabetes | 1.5 | 1.5 | 0 |
Type 2 Diabetes | 3.9 | 3.4 | 0.15 |
Ulcerative colitis | 1.4 | 2.8 | -1 |
Unhealthy Ageing | 3.1 | 1.2 | 1.58 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.